Naloxone B. Braun (Naloxone Hydrochloride)

Naloxone Hydrochloride, the active ingredient in Naloxone B. Braun, is an opioid antagonist presented as an injectable solution for intramuscular and intravenous use. It rapidly reverses life‑threatening respiratory depression caused by opioid overdose in emergency settings and is commonly stocked in hospitals and first‑response kits.

GNH USA supplies Naloxone B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable lead times and comprehensive after‑sales support.

Naloxone is an opioid antagonist used to counteract the effects of opioid agonists in acute overdose situations. - Opioid overdose: rapid reversal of life‑threatening respiratory depression and restored consciousness. - Opioid‑induced respiratory depression: restores adequate breathing in patients with opioid toxicity. - Opioid toxicity: counteracts central nervous system depression and reduces risk of fatal outcomes.

Naloxone may be associated with a range of adverse reactions, most of which are transient and related to rapid opioid withdrawal.

Common Side Effects: - Nausea - Sweating - Tachycardia

Serious or Rare Side Effects: - Severe hypertension or arrhythmias - Pulmonary edema - Anaphylactic reaction

When using naloxone, clinicians should observe specific safety measures to minimize risks and ensure effective reversal of opioid effects. - Assess airway and breathing before administration: confirm need for opioid reversal. - Avoid use in patients with known hypersensitivity to naloxone: discontinue if reaction occurs. - Monitor cardiovascular status after reversal: watch for hypertension or arrhythmias. - Anticipate acute opioid withdrawal: be prepared to manage agitation, pain, or vomiting. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Naloxone can interact with other substances, influencing its efficacy or precipitating adverse events.

Major Interactions (Avoid): - Opioid agonists: may cause abrupt withdrawal and severe sympathetic activation. - Mixed agonist‑antagonist opioids (e.g., buprenorphine): can reduce naloxone effectiveness.

Moderate Interactions (Monitor Closely): - Benzodiazepines: residual sedation may persist after opioid reversal. - Alcohol: additive central nervous system depression may remain. - Tricyclic antidepressants: increased risk of seizures during rapid opioid antagonism.